Glenmark Pharma shares up 2% after FDA grants fast track status to cancer drug
Glenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated RRMM patients. The tri-specific antibody showed high response rates and a favorable safety profile in early trials. Complete results will be presented at (...)
Site référencé: The Economic Times
The Economic Times
ETMarkets Smart Talk | Scientific investing over social media tips : Vikas Gupta urges method over hype
5/05/2025
ETMarkets Smart Talk : From Gold to large caps—where smart money is moving to build wealth, Ashutosh Tiwari decodes
5/05/2025
DMart shares slide 3% after brokerages trim target prices post Q4 show
5/05/2025
Dollar gets limited lift from jobs, trade questions linger
5/05/2025
Manipal, IHH, EQT & others eye Sahyadri Hospitals in Rs 5,000 crore bidding war
5/05/2025
Nifty could move higher towards 24,857–25,000 : Analysts
5/05/2025
